Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
dc.rights.license | open | en_US |
dc.contributor.author | RYOM, L. | |
dc.contributor.author | DILLING LUNDGREN, J. | |
dc.contributor.author | REISS, P. | |
dc.contributor.author | KIRK, O. | |
dc.contributor.author | LAW, M. | |
dc.contributor.author | ROSS, M. | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | MORLAT, Philippe | |
dc.contributor.author | ANDREAS FUX, C. | |
dc.contributor.author | FONTAS, E. | |
dc.contributor.author | DE WIT, S. | |
dc.contributor.author | D'ARMINIO MONFORTE, A. | |
dc.contributor.author | EL-SADR, W. | |
dc.contributor.author | PHILLIPS, A. | |
dc.contributor.author | INGRID HATLEBERG, C. | |
dc.contributor.author | SABIN, C. | |
dc.contributor.author | MOCROFT, A. | |
dc.date.accessioned | 2020-07-13T10:05:40Z | |
dc.date.available | 2020-07-13T10:05:40Z | |
dc.date.issued | 2019-10-08 | |
dc.identifier.issn | 0022-1899 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/10425 | |
dc.description.abstractEn | BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD. CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed. | |
dc.language.iso | EN | en_US |
dc.subject.en | MORPH3Eus | |
dc.title.en | Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study | |
dc.title.alternative | J Infect Dis | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1093/infdis/jiz369 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 31504669 | en_US |
bordeaux.journal | The Journal of infectious diseases | en_US |
bordeaux.page | 1629-1634 | en_US |
bordeaux.volume | 220 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 10 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-02898044 | |
hal.version | 1 | |
hal.date.transferred | 2020-07-13T10:05:45Z | |
hal.export | true | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.date=2019-10-08&rft.volume=220&rft.issue=10&rft.spage=1629-1634&rft.epage=1629-1634&rft.eissn=0022-1899&rft.issn=0022-1899&rft.au=RYOM,%20L.&DILLING%20LUNDGREN,%20J.&REISS,%20P.&KIRK,%20O.&LAW,%20M.&rft.genre=article |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |